{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T13:34:42Z","timestamp":1793108082679,"version":"4.5.0"},"reference-count":25,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,11,2]],"date-time":"2020-11-02T00:00:00Z","timestamp":1604275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["atherosclerosis-journal.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Atherosclerosis"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1016\/j.atherosclerosis.2020.10.013","type":"journal-article","created":{"date-parts":[[2020,10,10]],"date-time":"2020-10-10T01:16:21Z","timestamp":1602292581000},"page":"33-40","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects"],"prefix":"10.1016","volume":"314","author":[{"given":"Mariko","family":"Harada-Shiba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shazia","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel A.","family":"Gipe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evelyn","family":"Gasparino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1578-1714","authenticated-orcid":false,"given":"Vladimir","family":"Son","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Pordy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberico L.","family":"Catapano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2019","key":"10.1016\/j.atherosclerosis.2020.10.013_bib1","first-page":"e1082","article-title":"AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology\/American Heart Association task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2018","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib2","author":"World Health Organization"},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib3","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCRESAHA.118.313245","article-title":"Cholesterol-lowering agents","volume":"124","author":"Hadjiphilippou","year":"2019","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib4","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.jacbts.2019.05.008","article-title":"Angiopoietin-like 3: from discovery to therapeutic gene editing","volume":"4","author":"Wang","year":"2019","journal-title":"JACC Basic Transl. Sci."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib5","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1093\/eurheartj\/ehu274","article-title":"Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society","volume":"35","author":"Cuchel","year":"2014","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib6","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12944-017-0488-4","article-title":"Genetic determinants of inherited susceptibility to hypercholesterolemia - a comprehensive literature review","volume":"16","author":"Paththinige","year":"2017","journal-title":"Lipids Health Dis."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib7","doi-asserted-by":"crossref","first-page":"17093","DOI":"10.1038\/nrdp.2017.93","article-title":"Familial hypercholesterolaemia","volume":"3","author":"Defesche","year":"2017","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib8","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1093\/eurheartj\/ehw028","article-title":"Mutations causative of familial hypercholesterolaemia: screening of 98 098 individuals from the Copenhagen General Population Study estimated a prevalence of 1 in 217","volume":"37","author":"Benn","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.atherosclerosis.2016.10.017","article-title":"HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom","volume":"255","author":"France","year":"2016","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib10","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The agenda for familial hypercholesterolemia: a scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib11","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1056\/NEJMc1705994","article-title":"ANGPTL3 inhibition in homozygous familial hypercholesterolemia","volume":"377","author":"Gaudet","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib14","doi-asserted-by":"crossref","first-page":"402","DOI":"10.5551\/jat.38216","article-title":"Efficacy and safety of lomitapide in Japanese patients with homozygous familial hypercholesterolemia","volume":"24","author":"Harada-Shiba","year":"2017","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib15","doi-asserted-by":"crossref","first-page":"751","DOI":"10.5551\/jat.CR003","article-title":"Guidelines for diagnosis and treatment of familial hypercholesterolemia 2017","volume":"25","author":"Harada-Shiba","year":"2018","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib16","doi-asserted-by":"crossref","first-page":"679","DOI":"10.5551\/jat.RV17033","article-title":"Familial hypercholesterolemia and lipoprotein apheresis","volume":"26","author":"Makino","year":"2019","journal-title":"J. Atherosclerosis Thromb."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib17","doi-asserted-by":"crossref","first-page":"27561","DOI":"10.1074\/jbc.M110.144279","article-title":"Angiopoietin-like protein 3 inhibits lipoprotein lipase activity through enhancing its cleavage by proprotein convertases","volume":"285","author":"Liu","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib18","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1002926","article-title":"Exome sequencing, ANGPTL3 mutations, and familial combined hypolipidemia","volume":"363","author":"Musunuru","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib19","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1056\/NEJMoa1612790","article-title":"Genetic and pharmacologic inactivation of ANGPTL3 and cardiovascular disease","volume":"377","author":"Dewey","year":"2017","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.atherosclerosis.2020.10.013_bib20","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1161\/CIRCRESAHA.120.317128","article-title":"LDL-cholesterol reduction by ANGPTL3 inhibition in mice is dependent on endothelial lipase","volume":"127","author":"Wu","year":"2020","journal-title":"Circ. Res."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib21","doi-asserted-by":"crossref","DOI":"10.1194\/jlr.RA120000888","article-title":"Angiopoietin-like protein 3 (ANGPTL3) governs LDL-cholesterol levels through endothelial lipase-dependent VLDL clearance","author":"Adam","year":"2020","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib22","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa2004215","article-title":"Evinacumab for homozygous familial hypercholesterolemia","volume":"383","author":"Raal","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib23","author":"ICH"},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1161\/CIRCULATIONAHA.118.039107","article-title":"Inhibition of angiopoietin-like protein 3 with a monoclonal antibody reduces triglycerides in hypertriglyceridemia","volume":"140","author":"Ahmad","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib25","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bcp.13767","article-title":"Lack of ethnic differences in the pharmacokinetics and pharmacodynamics of evolocumab between Caucasian and Asian populations","volume":"85","author":"Wang","year":"2019","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib26","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3999\/jscpt.50.73","article-title":"Pharmacokinetics and pharmacodynamics of alirocumab, and effects on PCSK9 and low-density lipoprotein cholesterol, in Japanese and non-Japanese patients","volume":"50","author":"Hurbin","year":"2019","journal-title":"Rinsho yakuri\/Jpn. J. Clin. Pharmacol. Therapeut."},{"key":"10.1016\/j.atherosclerosis.2020.10.013_bib27","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s40262-018-0669-y","article-title":"Population pharmacokinetic analysis of alirocumab in healthy volunteers or hypercholesterolemic subjects using a michaelis-menten approximation of a target-mediated drug disposition model-support for a biologics license application submission: Part I","volume":"58","author":"Martinez","year":"2019","journal-title":"Clin. Pharmacokinet."}],"container-title":["Atherosclerosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020305761?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0021915020305761?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T16:25:34Z","timestamp":1762187134000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0021915020305761"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,12]]},"references-count":25,"alternative-id":["S0021915020305761"],"URL":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.10.013","relation":{},"ISSN":["0021-9150"],"issn-type":[{"value":"0021-9150","type":"print"}],"subject":[],"published":{"date-parts":[[2020,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A randomized study investigating the safety, tolerability, and pharmacokinetics of evinacumab, an ANGPTL3 inhibitor, in healthy Japanese and Caucasian subjects","name":"articletitle","label":"Article Title"},{"value":"Atherosclerosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.atherosclerosis.2020.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}